Rucaparib (AG-014699,PF-01367338) phosphate

製品コードS1098

Rucaparib (AG-014699,PF-01367338) phosphate化学構造

分子量(MW):421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ 価格(税別)  
In DMSO JPY 24200
JPY 21900
JPY 36800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(31)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
特性 The first PARP inhibitor used in clinical trials combined with temozolomide.
ターゲット
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M1\zSWZ2dmO2aX;uJGF{e2G7 M1HjVVAvOS9zL{WwNE8yODByIH7N M1jUTolvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6P MmD1NlUyOjh2NUW=
BT474 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrqW2c5PTByIH7N MXixNQKBmzF3wrDk MlXEdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M3XvNVI2OTJ6NEW1
SKBR3 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fzOVUxOCCwTR?= M1rLZ|Ex6oDVMUZCpIQ> NVjG[XljemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? NVXme5RnOjVzMki0OVU>
AU565 M{nLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jUTVUxOCCwTR?= MnPVNVDjiJNzNdMg[C=> MXfy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 MVuyOVEzQDR3NR?=
EFM192A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XJeVUxOCCwTR?= Ml3jNVDjiJNzNdMg[C=> MU\y[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 NI\0TIEzPTF{OES1OS=>
MDA-MB-231 M{nB[mZ2dmO2aX;uJGF{e2G7 M1z3NlExNzJyL{SwJO69VQ>? MUCyOEBp NGrw[VNqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIm5cowzPDR{MEG1Ni=>
MDA-MB-231 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2nJR|AvOS12MDFOwG0> NF3GfXgzPCCq M{HSOGlEPTEkgJm95qCKOTdwN{hCpO69VQ>? NHTDdI0zPDR{MEG1Ni=>
MDA-MB-231 MkjIRZBweHSxc3nzJGF{e2G7 Mlz2NVAwOjBxNECg{txO MWKyOEBp NVrsVWx7cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MmrINlQ1OjBzNUK=
MDA-MB-231 NXi1UpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPkNVAwOjBxNECg{txO MUSyOEBp MXHicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn NHO0Xo4zPDR{MEG1Ni=>
H460 M2TZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX20NFAhdk1? NHfPeoYzPMLiaB?= MXXpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= NWqxXFZpOjR2MUG2NVE>
A549  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln0OFAxKG6P M2LVUFI1yqCq MVzpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= MViyOFQyOTZzMR?=
DT40 M1\xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjr[VdZUUN3ME2yNUBvVQ>? M3joO|I1OzV4OEGz
DU145 NEm3XVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j3fmlEPTB;MUigcm0> MnryNlQ{PTZ6MUO=
COLO704 M33PdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwNUKgxtEhOC54NzFOwG0> MnK5NlM4Ojl2MEK=
OVMANAb MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzUNGU3UUN3ME2yMlU5KMLzIECuN|gh|ryP M4TOU|I{PzJ7NECy
OV177 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7JUGd{UUN3ME2yMlc5KMLzIECuO|Eh|ryP Mnn1NlM4Ojl2MEK=
OAW28 NV3RcFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwNkGgxtEhOC5{ODFOwG0> NUHtUmFlOjN5Mkm0NFI>
OVSAHO NYTDeIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwNkSgxtEhOC5|MzFOwG0> MXSyN|czQTRyMh?=
OVKATE MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfUTWM2OD1|Lk[0JOKyKDFwN{mg{txO NYTrVFJTOjN5Mkm0NFI>
OVCAR3 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjLepZzUUN3ME2zMlc1KMLzIECuOFAh|ryP NV\PU25JOjN5Mkm0NFI>
PEO14 NVfMd5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH76SlRKSzVyPUOuPFQhyrFiMD63OkDPxE1? NYDNSYU6OjN5Mkm0NFI>
A2780 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrKN2ZWUUN3ME2zMlk1KMLzIECuNlUh|ryP MXOyN|czQTRyMh?=
OVTOKO MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPme25RUUN3ME20MlE1KMLzIEGuOVMh|ryP NXjJ[nRyOjN5Mkm0NFI>
KURAMOCHIb NF;qXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XrbmlEPTB;ND6zOEDDuSByLkK5JO69VQ>? NHPrV4QzOzd{OUSwNi=>
TOV21G NVTZ[WRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTVwMEegxtEhOS5|MDFOwG0> M1XDNVI{PzJ7NECy
OVISE NHvFNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Pjb2lEPTB;NT62PEDDuSByLkKzJO69VQ>? Ml\6NlM4Ojl2MEK=
KK NVGwbY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:wdZZRUUN3ME22MlE2KMLzIEGuOFIh|ryP MY[yN|czQTRyMh?=
RMUGS NIPUZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\qNmlEPTB;Nz6wN{DDuSBzLkizJO69VQ>? NV3tPHJQOjN5Mkm0NFI>
PEO6 M1vzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnFNFRKSzVyPUeuNFYhyrFiMD63OEDPxE1? MoWwNlM4Ojl2MEK=
OVCA429 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRThwMkmgxtEhOS54NDFOwG0> MUOyN|czQTRyMh?=
OV167 NWrlb2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDTTWM2OD16LkOzJOKyKDFwMUig{txO Mn;vNlM4Ojl2MEK=
RMG1 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHewNYNKSzVyPUmuN|IhyrFiMj6zOkDPxE1? NXzn[HBMOjN5Mkm0NFI>
OVCAR5 NGn1WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwNUCgxtEhOi53OTFOwG0> NH7mclQzOzd{OUSwNi=>
EFO21 NV7ZfYk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjNZo5KSzVyPUmuPVIhyrFiMT64O{DPxE1? NXnmbW5QOjN5Mkm0NFI>
ES2 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFyLkGyJOKyKDFwMkOg{txO Mn31NlM4Ojl2MEK=
Tyk-nu M4rYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITBWo1KSzVyPUGwMlIxKMLzIEGuNVIh|ryP NXXZToxiOjN5Mkm0NFI>
CAOV3 M2XCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFyLkO3JOKyKDBwOEeg{txO NGS0c4IzOzd{OUSwNi=>
OV207 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF{LkK3JOKyKDBwM{Kg{txO Mn7nNlM4Ojl2MEK=
HEY MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF|LkCxJOKyKDBwN{Wg{txO NF7sbHkzOzd{OUSwNi=>
DOV13 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7FWppKSzVyPkG1JO69VQ>? NFHPS|QzOzd{OUSwNi=>
EFO27 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXJR21KSzVyPkG1JO69VQ>? MoPWNlM4Ojl2MEK=
HEY C2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Kye2lEPTB-MUWg{txO M4Ttb|I{PzJ7NECy
KOC-7cc NEPh[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWyRWJKSzVyPkG1JO69VQ>? MXeyN|czQTRyMh?=
MCASb MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyycmtiUUN3ME6xOUDPxE1? NWDUW4NtOjN5Mkm0NFI>
OAW42 MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2OD5zNTFOwG0> M3HobFI{PzJ7NECy
OV2008 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTQTWM2OD5zNTFOwG0> NHH5dVQzOzd{OUSwNi=>
OV90 NUPRbXFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRjF3IN88US=> M2nr[|I{PzJ7NECy
OVCA420b M{nSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljpTWM2OD5zNTFOwG0> MWOyN|czQTRyMh?=
OVCA432 NHnHcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRjF3IN88US=> MX[yN|czQTRyMh?=
PEA2 NF7mdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRjF3IN88US=> NEnZeZQzOzd{OUSwNi=>
SKOV3 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zoTmlEPTB-MUWg{txO NFezdJEzOzd{OUSwNi=>
TOV112D M3fSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX2boZ4OC1|IN88US=> MlPmTWM2OD5zNTFOwG0> NFvCNIwzOzd{OUSwNi=>
C4-2 M2f3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVMh|ryP NXTzOGcxOTRiZB?= MU\EUXNQ MV3k[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NYXDWXFoOjN3NkWyOFQ>
PC3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK0Wog3OC1|IN88US=> NEPDUGkyPCCm NEnJZlBFVVOR NH2zfZNl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MkDmNlM2PjV{NES=
DU145 NGH0VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W3SFAuOyEQvF2= Moq2NVQh\A>? MUnEUXNQ MmjY[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MWWyN|U3PTJ2NB?=
VCaP  MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjwWY1xOC1|IN88US=> MX2xOEBl NX7HUmFFTE2VTx?= NHzNVm5l\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 NHPWVlgzOzV4NUK0OC=>
LNCaP  NGO5UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTwNE0{KM7:TR?= MnzSNVQh\A>? M4HzcmROW09? M3:yNIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NHrKfZgzOzV4NUK0OC=>
MDA-MB-468 MlPrR4VtdCCYaXHibYxqfHliQYPzZZk> M{TENWlEPTB;OT63JO69VQ>? NHfvOokzOjZ5OEG2NS=>
MDA-MB-231 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGfsW4hKSzVyPUGzJO69VQ>? M37wflIzPjd6MU[x
Cal-51 NHHSOI9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4O5SWlEPTB;OD62JO69VQ>? MU[yNlY4QDF4MR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
体内試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
細胞試験: [4]
+ 展開
  • 細胞株: D425Med, D283Med and D384Med cells
  • 濃度: 0.4 μM
  • 反応時間: 3 or 5 days
  • 実験の流れ: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: CD-1 nude mice bearing established D283Med xenografts
  • 製剤: Normal saline
  • 投薬量: 1 mg/kg
  • 投与方法: One or four daily by i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03840200 Not yet recruiting Breast Cancer|Prostate Cancer|Ovarian Cancer Hoffmann-La Roche March 22 2019 Phase 1|Phase 2
NCT03795272 Not yet recruiting Cervical Cancer Nordic Society for Gynaecologic Oncology|Institute of Cancer Research United Kingdom|Central and Eastern European Oncology Group|North Eastern Germany Society of Gynaecologic Oncology|Belgian Gynaecological Oncology Group|Princess Margaret Hospital Canada|PGOG (Polish Gynaecologic Oncology Group)|GSO Global Clinical Research BV|GCP-enhederne March 1 2019 Phase 2
NCT03639935 Recruiting Biliary Tract Cancer University of Michigan Rogel Cancer Center|Dana-Farber Cancer Institute|Vanderbilt University Medical Center March 2019 Phase 2
NCT03617679 Recruiting Metastatic Endometrial Cancer University of Colorado Denver|Clovis Oncology Inc.|National Cancer Institute (NCI) March 6 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Rucaparib (AG-014699,PF-01367338) phosphateを買う | Rucaparib (AG-014699,PF-01367338) phosphate ic50 | Rucaparib (AG-014699,PF-01367338) phosphate供給者 | Rucaparib (AG-014699,PF-01367338) phosphateを購入する | Rucaparib (AG-014699,PF-01367338) phosphate費用 | Rucaparib (AG-014699,PF-01367338) phosphate生産者 | オーダーRucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate化学構造 | Rucaparib (AG-014699,PF-01367338) phosphate分子量 | Rucaparib (AG-014699,PF-01367338) phosphate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID